Participated · Series C · Apr 2024

AtaCor Medical is a San Clemente, CA-based medical device company advancing extravascular cardiac rhythm management technology. Its core products include a proprietary extravascular temporary pacing lead system and a third-generation EV-ICD lead. The company’s technology aims to provide benefits of traditional transvenous implantable cardiac defibrillation and temporary pacing without placing leads or devices in the heart or vascular system, preserving the heart for future care. AtaCor plans to use the new financing to support an FDA submission for its extravascular temporary pacing lead and to complete a pilot study for the third-generation EV-ICD lead system. Led by CEO Rick Sanghera, management says the investment will advance clinical and regulatory milestones. The company is positioning its novel products to bring them to patients. AtaCor Medical is developing a novel extracardiac pacing system designed to provide cardiac pacing without placing hardware on or inside the heart. The extracardiac lead is intended to be inserted without medical imaging, avoids vascular access, and leaves the heart untouched. The design aims to eliminate bedrest restrictions associated with temporary pacing and to improve patient mobility and post-procedural recovery. The technology has completed early clinical evaluation and the company is developing the system for both temporary and permanent pacing markets. AtaCor plans to use new funding to finish development, build additional clinical evidence, and pursue US and EU regulatory clearances. The company was established in 2014, its management team has over 80 years of combined experience, and the extracardiac pacing system is not yet approved for sale in any geography. AtaCor Medical is developing a novel extravascular substernal cardiac pacing system that requires no hardware to be placed inside or onto the patient’s heart. The substernal lead is inserted without the need for medical imaging, avoids vascular access, and leaves the heart untouched. The design aims to eliminate bedrest restrictions associated with temporary pacing and to improve post-procedural mobility and recovery. The technology is being developed for both temporary and permanent pacing markets and targets treatment of transient and chronic bradycardia, including temporary pacing needs tied to TAVR procedures. The company is not yet approved for sale in any geography. The $8.8M Series A financing will support continued development efforts. AtaCor was established in 2014 and is based in San Clemente, California; its management team brings over 80 years of combined experience in implantable cardiac devices and electrophysiology.